Eddison Research dated 30th March 2015 (as previously posted)
Extracts from Valuation
"Mesoblast’s share price has trickled downward over the past year just as its pipeline is beginning to make significant traction, with first product approval likely in aGvHD in the coming months and two ongoing pivotal Phase III trials".
"With no clear rationale for the shares languishing, we cite key upcoming potential catalysts that could allow for share price inflections. These include approval of MSC-100-IV for aGvHD in Japan (2015), interim analysis of the current Phase III trial in CHF (H115) and Phase II data for MPC-300-IV in both diabetic kidney disease (H115) and rheumatoid arthritis (H215) ".
In my view Edison is as autonomous as an analyst can be who thinks stock is positive.
There not investment bankers and operate as a research house.
Anyway - my opinion only.
Please DYOR ..
Eddison Research dated 30th March 2015 (as previously posted)...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
0.080(8.25%) |
Mkt cap ! $1.198B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.06 | 99.0¢ | $4.930M | 4.779M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 23545 | $1.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 339479 | 5 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |